Immunome (NASDAQ:IMNM) Receives Outperform Rating from Wedbush

Immunome (NASDAQ:IMNM - Get Free Report)'s stock had its "outperform" rating restated by analysts at Wedbush in a note issued to investors on Tuesday, RTT News reports. They presently have a $33.00 target price on the stock. Wedbush's price objective suggests a potential upside of 124.18% from the stock's current price.

Other analysts also recently issued research reports about the company. Leerink Partnrs reaffirmed an "outperform" rating on shares of Immunome in a research note on Monday, January 29th. SVB Leerink initiated coverage on shares of Immunome in a research note on Monday, January 29th. They set an "outperform" rating and a $30.00 target price on the stock. Guggenheim started coverage on shares of Immunome in a report on Monday, April 15th. They issued a "buy" rating and a $35.00 price objective for the company. Finally, JPMorgan Chase & Co. began coverage on Immunome in a report on Tuesday, April 30th. They set an "overweight" rating and a $24.00 target price on the stock. Seven analysts have rated the stock with a buy rating, According to MarketBeat, Immunome presently has an average rating of "Buy" and an average target price of $30.50.

Immunome Stock Performance

Shares of NASDAQ IMNM traded down $0.89 during midday trading on Tuesday, hitting $14.72. The company's stock had a trading volume of 1,131,192 shares, compared to its average volume of 735,211. Immunome has a 1-year low of $4.50 and a 1-year high of $30.96. The firm's fifty day moving average price is $19.77 and its 200-day moving average price is $15.74. The firm has a market cap of $882.32 million, a P/E ratio of -2.73 and a beta of 1.87.

Immunome (NASDAQ:IMNM - Get Free Report) last issued its earnings results on Thursday, March 28th. The company reported ($0.54) EPS for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.26). The company had revenue of $3.83 million during the quarter, compared to analyst estimates of $3.40 million. Immunome had a negative net margin of 761.92% and a negative return on equity of 69.74%. As a group, research analysts predict that Immunome will post -1.91 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Immunome

Several large investors have recently modified their holdings of the stock. Dorsey Wright & Associates acquired a new position in Immunome during the third quarter valued at $26,000. EntryPoint Capital LLC lifted its stake in shares of Immunome by 21,864.0% in the first quarter. EntryPoint Capital LLC now owns 5,491 shares of the company's stock worth $136,000 after buying an additional 5,466 shares during the last quarter. Jump Financial LLC bought a new stake in shares of Immunome during the 4th quarter worth $172,000. Sei Investments Co. acquired a new stake in shares of Immunome in the first quarter valued at about $469,000. Finally, Clear Creek Financial Management LLC acquired a new position in shares of Immunome during the 1st quarter worth about $547,000. 44.58% of the stock is owned by institutional investors.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.